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Abstract
Background  and  objective:  Autotitrating  positive  airway  pressure  (APAP)  is  an  accepted  titra-
tion method  to  determine  the  optimal  positive  airway  pressure  (PAP),  for  the  treatment  of
obstructive  sleep  apnea  (OSA).  The  required  duration  of  APAP  monitoring  to  determine  a  fixed
continuous positive  airway  pressure  level  still  remains  to  be  established.  We  aimed  to  evaluate
the variation  in  PAP  level,  delivered  by  APAP  devices,  at  different  periods  of  treatment,  to
determine the  APAP  treatment  duration  required  to  reach  an  effective  and  stable  PAP  level.
Methods:  A  cross-sectional  study  of  62  patients  newly  diagnosed  with  OSA  were  evaluated  after
3 months  of  APAP  therapy.  APAP  data  corresponding  to  the  first  day  (D1),  first  week  (W1),  seventh
week (W7)  and  twelfth  week  (W12)  under  APAP  therapy  was  collected.  For  the  analysis  of  the
pressure  behaviour,  the  difference  of  P95th  pressure  level  between  W12  and  W7  (P  W12--W7),
W12 and  W1  (P  W12--W1)  and  W12  and  D1  (P  W12--D1)  was  calculated.
Results:  There  was  a  high  correlation  in  P95th  pressure  level  between  D1  and  W12  (r  =  0.771;
p >  0.0001),  W1  and  W12  (r  =  0.817;  p  >  0.0001),  and  W7  and  W12  (r  =  0.926;  p  >  0.0001).  This
correlation  progressively  increased  with  APAP  use.  A  significance  difference  was  found  in  con-
cordance between  P  W12--W7  and  P  W12--D1  (p  =  0.046)  within  the  pressure  range  ±2  cmH2O.
However there  was  no  significant  difference  in  concordance  between  P  W12--W7  and  P  W12--W1.
Conclusions:  One  week  of  APAP  therapy  seems  sufficient  to  determine  an  effective  and  stable
PAP level,  within  the  pressure  range  ±2  cmH2O.
© 2017  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Please  cite  this  article  in  press  as:  Dias  C,  et  al.  Rev  Port  Pneumo
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ntroduction
bstructive  sleep  apnea  syndrome  (OSAS)  is  a  common
isorder  affecting  at  least  2%--4%  of  adult  population.1 Con-
inuous  positive  airway  pressure  (CPAP)  is  considered  the
reatment  of  choice  of  OSAS.  There  are  several  methods
sed  to  determine  the  pressure  level  for  CPAP  therapy,
amely,  a  full-night  manual  titration  in  a  sleep  laboratory,
 split-night  diagnostic  titration  and  certain  autotitrating
ositive  airway  pressure  (APAP)  devices.  A  full-night  man-
al  titration  in  a  sleep  laboratory  is  considered  the  best,1 as
t  allows  direct  observation  for  conducting  pressure  selec-
ion,  being  able  to  adjust  the  fit  of  the  mask,  eliminating
eaks  and  helping  the  patient  adapt  to  CPAP.1,2 However,
here  are  some  limitations  associated  with  this  practice;  the
osts  and  time  involved  in  repeat  polysomnography  (PSG)
ue  to  incomplete  titrations,  laboratory  versus  home  envi-
onment  and  limited  ‘‘one-night’’  sampling.2,3 APAP  devices
re  able  to  detect  the  airflow  and  pressure  in  the  circuit,
s  well  as  the  occurrence  of  respiratory  events.  It  is  possi-
le  to  determine  the  appropriate  pressure  through  the  data
btained  from  APAP  tracking  systems  registration,  with  sim-
lar  adherence  and  outcomes,  and  it  is  more  cost-effective,
ompared  to  manual  laboratory  CPAP  titration.2,4 Many  cli-
icians  prescribe  CPAP  based  on  automatic  titration  rather
han  manual  titration.  However,  the  required  duration  of
PAP  monitoring  to  determine  a  fixed  CPAP  level  still  remains
o  be  established.2,5
The  aim  of  this  study  was  to  evaluate  the  variation  in  pos-
tive  airway  pressure  (PAP)  level  of  APAP  devices  at  different
eriods  of  treatment,  up  until  12  weeks,  in  CPAP-naïve
atients  with  obstructive  sleep  apnea  (OSA),  in  order  to
etermine  the  APAP  treatment  time  required  to  reach  an
ffective  and  stable  PAP  level.
ethods
ubjects  and  study  design
e  carried  out  a  cross-sectional  study  that  included  con-
ecutive  adult  patients  with  newly  diagnosed  OSA  followed
n  the  Sleep  Medicine  Centre  --  Centro  Hospitalar  e  Uni-
ersitário  de  Coimbra,  during  a  two-month  period,  from
arch  2014.  Recruited  patients  initiated  APAP  therapy
nd  were  evaluated  in  consultation  with  a  sleep  physi-
ian  at  3  months.  Information  concerning  gender,  age,
nitial  body  mass  index  (BMI),  neck  circumference  (NC),  ini-
ial  and  follow-up  Epworth  Sleepiness  Scale  (ESS)  score,
pnea--hypopnea  index  (AHI)  and  APAP  data  (downloaded
uring  the  clinical  consult)  was  collected.
Diagnosis  of  OSA  was  obtained  with  a  level  3  sleep  study
evice  (Alice  PDx,  Embletta  X100,  Nox  T3  or  Stardust  II)
t  the  patient’s  home  with  unattended  recording.  The  fol-
owing  morning  sleep  studies  were  manually  scored  by  an
xperienced  sleep  technician  according  to  the  criteria  of
he  American  Academy  of  Sleep  Medicine,6 and  APAP  therapyPlease  cite  this  article  in  press  as:  Dias  C,  et  al.  Rev  Port  Pneumo
as  immediately  prescribed  by  a  sleep  physician  if  criteria
or  treatment  were  present,  namely:  AHI  ≥  30  events  per
our;  AHI  ≥  15  events  per  hour  with  associated  symptoms  or
ardiovascular  comorbidities  and  AHI  =  5--15  events  per  hour
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ith  significant  and  intolerable  symptoms  not  explained  by
ther  factors.1
Patients  were  excluded  if  any  of  the  following  criteria
ere  present:  previous  use  of  PAP  device,  previous  pharyn-
eal  OSA  surgery,  chronic  nasal  obstruction,  hypoventilation
isorders,  a  predominance  of  central  events,  malignancy,
ognitive  disability  and  incomplete  medical  data.
PAP and adherence data
he  APAP  devices  were  S8  AutoSpirit  IITM and  S9  AutoSetTM
Resmed,  North  Ryde,  Australia),  with  nose  and  face  masks
ptimized  for  the  facial  structure  and  comfort  of  the
atient.  Devices  were  chosen  randomly.  Heated  humidifiers
ere  prescribed  when  necessary,  only  after  the  beginning  of
reatment.  APAP  data  collected  included:  air  leaks  at  95th
ercentile  (P95th),  air  pressure  delivered  (P95th),  residual
HI  and  adherence  data  from  the  first  day  (D1),  the  first
eek  (W1),  the  seventh  week  (W7)  and  twelfth  week  (W12)
nder  APAP  therapy.  The  titration  pressure  level  assumed  to
e  effective  in  treating  the  majority  of  events  was  defined
s  the  95th  percentile  pressure  level,  which  means  that  sub-
ects  spent  95%  of  the  recording  time  below  this  pressure.
or  the  analysis  of  the  pressure  behaviour,  the  difference  of
he  P95th  pressure  level  between  W12  and  W7  (P  W12--W7),
12  and  W1  (P  W12--W1)  and  W12  and  D1  (P  W12--D1)  were
alculated.
Adherence  data  included  percentage  of  days  of  APAP  use,
ercentage  of  days  of  APAP  use  of  more  than  4  h  and  median
f  hours  of  use  per  days  of  use.  Only  adherent  patients  (use
4  h/night  70%  of  the  nights)7,8 with  a  leak  lower  than  0.3  L/s
nd  an  AHI  <  5/h  at  the  last  evaluation  were  considered  for
he  pressure  behaviour  analysis.
Initial  analysis  compared  the  sample  characteristics  and
herapy  parameters  between  the  two  groups,  according  to
he  device  used,  in  order  to  exclude  any  significant  bias,
s  both  detect  flow  limitation  but  are  driven  by  different
herapy  algorithms.  Secondarily,  an  analysis  of  the  whole
ample  was  performed.
nalysis
ontinuous  variables  were  expressed  as  mean  ±  standard
eviation.  Frequency  and  percentage  were  used  for  categor-
cal  data.  The  ANOVA  test  was  used  for  comparison  of  means
n  paired  samples.  Pearson’s  correlation  coefficient  was  used
o  evaluate  the  relation  between  P95th  pressure  level  at
12  and  the  other  periods.  The  Kendall  test  was  used  to  ana-
yze  the  concordance  between  PW12--W7  and  PW12--W1  and
etween  PW12--W7  and  PW12--D1,  within  the  pressure  range
f  ±2  cmH2O  (as  during  a  split-night  CPAP  titration  study,
he  American  Academy  of  Sleep  Medicine  recommends  an
ncrease  by  2  or  2.5  cmH2O  with  an  interval  no  shorter  than
 min  to  eliminate  obstructive  respiratory  events,  rather
han  an  increase  by  at  least  1  cmH2O,  given  the  shorterl.  2017.  http://dx.doi.org/10.1016/j.rppnen.2017.04.002
PAP  titration  duration).9 Results  were  considered  signifi-
ant  at  a  p  level  of  less  than  0.05.  Statistical  analysis  was
erformed  with  Statistical  Package  for  the  Social  Sciences
SPSS)  version  22.0.
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Table  1  Clinical  characteristics  and  adherence  data  of  APAP  therapy  of  study  population,  group  1  and  group  2.
Study  population  (n  =  62)  Group  1  (n  =  37)  Group  2  (n  =  25)  p  value  (group  1  vs.  group  2)
Age  mean,  years  63  ±  12  65.1  ±  10.2  60.3  ±  14.3  0.114
Gender (male/female)  62  (53/9)  34/3  19/5  0.081
BMI mean,  kg/m2 32.28  ±  5.27 31.7  ±  4.9 33.1  ±  5.8 0.304
Neck circumference,  mean  cm 43.2  ±  4 43  ±  4.2 43.4  ±  3.7 0.82
ESS score  (at  the  diagnosis)  13  ±  6  13.7  ±  5.4  12.8  ±  6  0.551
AHI/h (at  the  diagnosis)  40.2  ±22.76  44.5  ±20.81  33.8  ±24.43  0.071
ESS score  at  W12  7  ±  4.1  7.5  ±  3.9  7.2  ±  5  0.772
Residual AHI/h
D1  5.3  ±  6  4.9  ±  4.2  5.9  ±  8  0.522
W1 4.1  ±  3.8  4.1  ±  3.3  4.1  ±  4.5  0.999
W7 3.2  ±  2.7  3.6  ±  2.8  2.6  ±  2.4  0.151
W12 3  ±  2.5  3.3  ±  2.5  2.5  ±  2.5  0.182
Leak, L/s
D1  12.9  ±  7.5  13.6  ±  7.5  12.43  ±  7.4  0.187
W1 12.7  ±  7.2  13.26  ±  7.2  12  ±  7.2  0.210
W7 12.8  ±  7.8  13.25  ±  7.8  12.14  ±  7.9  0.140
W12 13.7  ±  8.1  14.29  ±  8.1  13  ±  8.2  0.167
Percentage  of  nights  use  >4  h  97  ±  3.8  97.4  ±  3.8  96.5  ±  3.8  0.382
Median use,  h/night  6.9  ±  0.9  7.1  ±  0.95  6.9  ±  0.85  0.182
Data are presented as mean values ± standard deviation. Group 1 -- device S8 AutoSpirit IITM; group 2 -- device S9 AutoSetTM; BMI body
mass index; ESS Epworth Sleepiness Scale, AHI apnea--hypopnea index. D1 first day under APAP; W1 first week under APAP; W7 seventh
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Results
Out  of  a  total  110  patients  with  OSA  and  APAP  therapy,  62
were  included,  according  to  the  selection  criteria.  Of  the
62  patients,  38  (61.2%)  received  S8  AutoSpirit  IITM (group  1)
and  24  (38.7%)  received  S9  AutoSetTM (group  2).  Descriptive
summary  statistics,  outcome  and  APAP  adherence  did  not
differ  between  groups,  in  accordance  with  the  device  used
(Table  1).  Relatively  to  the  OSA  severity,  12  (19.4%)  patients
had  a  mild  OSA,  17  (27.4%)  a  moderate  and  33  (53.2%)  a
severe  OSA.  There  was  no  significant  weight  change  during
follow-up  (data  not  shown).
The  APAP  devices  were  programmed  with  a  mean
lower  and  upper  pressure  set  to  5.8  ±  1.13  cmH2O  and
14.2  ±  1.1  cmH2O,  respectively.  There  were  no  differences
in  the  objective  compliance  of  APAP  therapy  or  leak  lev-
els  between  groups.  When  assessing  the  effectiveness  of
the  treatment,  there  were  no  differences  between  groups.
Both  mentioned  an  improvement  in  the  daytime  sleepiness,
estimated  with  ESS.  The  mean  residual  AHI  was  ≤5/h  after
APAP  therapy  initiation,  without  differences  between  groups
(Table  1).  The  apnea--hypopnea  index  reached  normal  lev-
els  at  W12  in  54  patients,  with  a  mean  value  2.23  ±  1.1/h  in
these  patients  (data  not  shown).
As  there  were  no  differences  in  general  features,  objec-
tive  compliance  and  effectiveness  of  treatment  in  both
device  groups,  the  analysis  of  pressure  behaviour  was  per-
formed  considering  the  study  population,  but  only  includingPlease  cite  this  article  in  press  as:  Dias  C,  et  al.  Rev  Port  Pneumo
the  patients  with  a  residual  AHI  <  5/h  at  the  last  evaluation
(n  =  54).  No  significant  differences  were  found  between  the
mean  values  of  air  pressure  delivered  at  P95th  at  the  four
periods  (Table  2).
A
d
A
mThe  concordance  rates,  within  the  range  ±2  cmH2O,
etween  the  P95th  pressure  level  at  W12  and  D1,  W12  and
1,  W12  and  W7  were  92.6%,  94.4%  and  100%,  respectively
Table  3).  Within  this  range,  a  significance  difference  was
ound  in  concordance  between  P  W12--W7  and  P  W12--D1
p  =  0.046;  Table  4),  however  there  was  no  significant  differ-
nce  in  concordance  between  P  W12--W7  and  P  W12--W1.
iscussion
n  this  study,  we  analyzed  the  variation  in  PAP  level  of  APAP
evices  at  four  different  periods  of  treatment,  up  until  12
eeks,  in  a  CPAP-naïve  population  with  OSA.  We  compared,
orrelated  and  evaluated  the  concordance  in  pressure  levels
etween  these  periods.
There  was  no  significant  difference  in  concordance
etween  the  difference  of  P95th  pressure  level  at  the  12th
eek  and  at  the  7th  week  and  between  the  difference  of
95th  pressure  level  at  the  12th  week  and  the  first  week
f  treatment,  within  the  pressure  range  ±2  cmH2O.  A  sig-
ificance  difference  was  found  in  concordance  between  the
ifference  of  P95th  pressure  level  at  the  12th  week  and  at
he  7th  week  and  between  the  difference  of  P95th  pressure
evel  at  the  12th  week  and  the  first  day  of  treatment.  This
esult  suggests  that  one  week  of  APAP  therapy  is  sufficient
o  determine  a  therapeutic  CPAP  level  requirement.
Literature  concerning  the  scope  of  this  study  is  limited;
onetheless  many  clinicians  prescribe  fixed  CPAP  based  onl.  2017.  http://dx.doi.org/10.1016/j.rppnen.2017.04.002
PAP  monitoring.  Currently,  there  are  devices  in  the  market
esigned  to  obtain  this  measure  automatically,  changing  the
PAP  mode  to  CPAP  mode  after  a  period  of  time.  Further-
ore,  in  some  settings  and  countries,  the  use  of  CPAP  over
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Table  2  Comparison  of  P95th  pressure  levels  reached  at  the  four  periods.
Mean  of  P95th  pressure  level  (cmH2O)  Study  population  (n  =  54)  p  value
P95th  D1  11.27  ±  1.53 0.407
P95th  W1  11.12  ±  1.53
P95th  W7 11.32  ±  1.66
P95th  W12 11.18  ±  1.62
P95th 95 percentile. There was a high correlation in P95th pressure level between D1 and W12 (r = 0.771; p > 0.0001), W1 and W12
(r = 0.817; p > 0.0001), and W7 and W12 (r = 0.926; p > 0.0001). This correlation progressively increased with APAP use.
Table  3  Concordance  in  effective  pressure  levels.
Concordance  with  P95th  pressure  level  at  W12  (n)
D1  W1  W7
Concordance  in  the  range  ±2  cmH2O  92.6%  (50)  94.4%  (51)  100%  (54)
P95th 95 percentile.
Table  4  Comparison  of  effective  level  pressure  concordance.
Concordance  between  P
W12--W7  and  P  W12--W1
(n)
p  value Concordance  between  P
W12--W7  and  P  W12--D1
(n)
p  value
Concordance  in  the  range  ±2  cmH2O 94.4%  (51)  0.083  92.6%  (50)  0.046a
PW12--W7 difference between the P95th pressure at W12 and W7; PW12--W1 difference between the P95th pressure at W12 and W1; P
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a Statistically significant result.
PAP  is  more  frequent  for  different  reasons--cost,  comfort,
fficacy,  etc.  However,  the  EPAP  chosen  for  the  CPAP  mode  is
requently  performed  using  the  automatic  algorithm  of  APAP
evices  and  not  with  an  overnight  PSG,  due  to  the  greater
ost  and  difficult  laboratory  access.  Therefore,  knowledge
bout  the  time  needed  for  an  APAP  device  to  establish  an
ffective  and  stable  fixed  EPAP  is  extremely  important  in
rder  not  to  extend  the  period  with  the  APAP  device  in  a
eaningless  way  nor  to  curtail  the  period  before  an  effective
PAP  measure  is  obtained.
Various  studies  analyzed  the  pressure  behaviour  with
PAP  therapy,  in  patients  with  OSA.  However,  to  the  best
f  our  knowledge,  an  APAP  monitoring  with  the  aim  of
etermining  stabilization  of  the  pressure  level  has  not  been
erformed.  Choi10 compared  2  weeks  of  auto-adjusted  titra-
ion  and  titration  using  a  predictive  equation  with  full  night
tandard  titration,  with  no  significant  difference  in  concord-
nce  between  auto-adjusting  titration  and  titration  using  an
quation  compared  to  manual  titration,  within  the  range
1  cmH2O.  Damiani  et  al.5 analyzed  the  titration  effective-
ess  of  two  APAP  devices,  during  one  night  with  each  device
two  consecutive  nights),  with  agreement  between  the
edian  pressure  level,  confirmed  with  portable  monitoring
n  laboratory  and  with  fixed  CPAP  at  the  APAP  recommended
ressures  (third  and  fourth  nights).  Bachour  et  al.11 tried  toPlease  cite  this  article  in  press  as:  Dias  C,  et  al.  Rev  Port  Pneumo
nd  the  optimal  APAP  trial  duration;  patients  received  APAP
uring  a  5-day  trial  at  home.  No  difference  was  found  in  the
ressure  variability  index  between  the  5  days.  Luo  et  al.12
eported  that  CPAP  from  automatic  titration  (3--5  nights)  was
f
f
d
pignificantly  higher  than  the  pressure  obtained  from  manual
itration.  Although  these  studies  have  different  aims,  some
esults  may  be  compared  to  our  findings.  It  is  worth  noting
he  short  duration  of  home  unattended  titration  (1  night  to  2
eeks)  which  does  not  provide  sufficient  time  to  obtain  sig-
ificant  differences  in  therapeutic  pressure  level.  A  delayed
ffect  of  CPAP  has  been  described.13 Series14 quantified  the
hanges  in  the  required  level  two  weeks  after  a  sleep  study
nd  after  2,  8  and  20  months  of  CPAP  therapy.  The  effective
PAP  level  progressively  decreased  with  time,  with  signif-
cant  differences  between  the  first  three  evaluations.  This
elayed  effect  of  CPAP  could  be  attributed  to  an  improve-
ent  in  upper  airway  morphology,15 and/or  to  the  correction
f  sleep  fragmentation.16 The  required  pressure  to  eliminate
bstructive  respiratory  events  varies  over  a night  depending
n  factors  like  alcohol,  hypnotic  agent  use,  body  position,
asal  obstruction  and  sleep  state.2,17 Additionally,  pressure
equirements  may  vary  over  time  due  to  weight  change,
ifferent  medical  condition  and  resolution  of  upper  airway
edema  caused  by  repetitive  apnea.18,19
Based  on  these  statements,  our  study  considered  a  longer
eriod  of  APAP  therapy,  compared  to  previous  studies.  Addi-
ionally,  three  evaluation  periods  corresponded  to  the  mean
ressure  values  of  three  separate  weeks  (W1,  W7  and  W12),
llowing  an  average  pressure  over  the  course  of  the  night,l.  2017.  http://dx.doi.org/10.1016/j.rppnen.2017.04.002
or  seven  consecutive  nights  in  three  different  weeks.  As
ar  as  we  know,  there  is  no  literature  about  the  required
uration  of  APAP  monitoring  required  to  prescribe  a  fixed
ressure,  and  our  study,  after  a  follow-up  of  12  weeks,
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Titration  with  automatic  continuous  positive  airway  pressur
showed  that  one  week  of  APAP  therapy  seems  sufficient  to
determine  an  effective  and  stable  fixed  pressure  level.
A  limitation  of  this  study  is  the  relatively  small  sample
size.
Conclusion
In  conclusion,  one  week  of  APAP  therapy  seems  sufficient  to
determine  an  effective  and  stable  PAP  level,  within  the  pres-
sure  range  ±2  cmH2O.  Future  studies,  with  a  larger  number
of  patients,  are  necessary  to  corroborate  these  findings.
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